No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul
Executive Summary
Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.
You may also be interested in...
Homeopathic Nasal Spray Firm Warned About Microbial Contamination Needs GMP Remediation
FDA advises additional recalls of Green Pharmaceuticals’ SnoreStop NasoSpray could be needed. Agency’s testing showed a batch of SnoreStop NasoSpray is adulterated because “it consists in whole or in part of any filthy, putrid, or decomposed substance.”
US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds
Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.
OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny
American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers.